What is SGMT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.63B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SGMT?

P/E (TTM) is n/a and 52-week range is $4.50 to $11.45 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SGMT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SGMT?

The company profile lists net income (TTM) near $-79M, EPS (TTM) near $-1.28 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Sagimet Biosciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Mateo, California, US, 61.8M shares outstanding, ISIN US7867001049 when available from company profile and filing metadata.

Sagimet Biosciences Inc

$SGMT

Health Care · Biotechnology

IR Run Scenarios

$8.93

+0.11%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. The company is headquartered in San Mateo, California and currently employs 16 full-time employees. The company went IPO on 2023-07-14. The firm's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The firm is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.

Employees

Website

sagimet.com/

IPO

2023-07-14

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)